Commonwealth Equity Services LLC Buys 1,500 Shares of Celcuity Inc. (NASDAQ:CELC)

Commonwealth Equity Services LLC increased its stake in shares of Celcuity Inc. (NASDAQ:CELC) by 9.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,624 shares of the company’s stock after purchasing an additional 1,500 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Celcuity were worth $272,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. BNP Paribas Financial Markets grew its stake in shares of Celcuity by 78.5% during the first quarter. BNP Paribas Financial Markets now owns 8,937 shares of the company’s stock valued at $193,000 after purchasing an additional 3,930 shares during the last quarter. Pale Fire Capital SE grew its stake in shares of Celcuity by 38.4% during the fourth quarter. Pale Fire Capital SE now owns 14,409 shares of the company’s stock valued at $210,000 after purchasing an additional 4,000 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in shares of Celcuity by 7.8% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 22,030 shares of the company’s stock valued at $361,000 after purchasing an additional 1,600 shares during the last quarter. Hennion & Walsh Asset Management Inc. bought a new stake in shares of Celcuity during the second quarter valued at approximately $888,000. Finally, Bank of New York Mellon Corp grew its stake in shares of Celcuity by 42.7% during the second quarter. Bank of New York Mellon Corp now owns 66,256 shares of the company’s stock valued at $1,085,000 after purchasing an additional 19,811 shares during the last quarter. 63.33% of the stock is owned by institutional investors.

Celcuity Trading Up 2.1 %

CELC opened at $14.28 on Wednesday. The firm’s fifty day moving average is $16.48 and its two-hundred day moving average is $16.82. The company has a debt-to-equity ratio of 0.54, a quick ratio of 14.95 and a current ratio of 14.95. The firm has a market cap of $501.24 million, a PE ratio of -5.14 and a beta of 0.76. Celcuity Inc. has a twelve month low of $8.39 and a twelve month high of $22.19.

Celcuity (NASDAQ:CELC) last posted its earnings results on Wednesday, August 14th. The company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.09. During the same quarter last year, the business earned ($0.66) earnings per share. Equities research analysts anticipate that Celcuity Inc. will post -2.54 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Leerink Partnrs raised shares of Celcuity to a “strong-buy” rating in a research note on Monday, July 22nd. Lifesci Capital assumed coverage on shares of Celcuity in a research note on Monday, August 26th. They issued an “outperform” rating and a $27.00 price objective on the stock. Stifel Nicolaus reduced their price objective on shares of Celcuity from $40.00 to $39.00 and set a “buy” rating on the stock in a research note on Thursday, August 15th. Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Celcuity in a research note on Thursday, August 15th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Celcuity in a research note on Thursday, August 15th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $28.67.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.